Abstract:Background: The American Thoracic Society convened an international, multidisciplinary panel to develop clinical practice guidelines for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). Objective: To conduct a systematic review and evaluate the literature to determine whether patients with SSc-ILD should be treated with cyclophosphamide. Data Sources: A literature search was conducted across the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases through June 2022 for studies using cyclophosphamide to treat patients with SSc-ILD. Data Extraction: Mortality, disease progression, quality of life, and adverse event data were extracted, and meta-analyses were performed when possible. The Grading of Recommendations, Assessment, Development and Evaluation Working Group method was used to assess the quality of evidence. Synthesis: Five studies were included; two randomized controlled trials compared cyclophosphamide versus placebo, and one randomized controlled trial and two retrospective case-control studies compared cyclophosphamide versus mycophenolate. Compared with placebo, there was a 2.83% reduction in the decline at 12 months for forced vital capacity (FVC) % predicted using cyclophosphamide (95% confidence interval [CI], 0.80-4.87; low evidence). There were improvements in breathlessness (Transition Dyspnea Index mean difference [MD], 2.90; 95% CI, 1.94-3.86; minimum clinically important difference, 1; moderate evidence) and disability (Health Assessment Questionnaire-Disability Index MD, -0.16; 95% CI, -0.28 to -0.04; minimum clinically important difference, -0.14; moderate evidence). There were increased risks of leukopenia and constitutional symptoms using cyclophosphamide, but no difference in mortality. When cyclophosphamide was compared with mycophenolate, there were differences in diffusing capacity of the lung for carbon monoxide % predicted favoring mycophenolate at 6 months (MD, -3.67%; 95% CI, -6.3% to -1.1% unadjusted; MD, -4.88%; 95% CI, -7.3% to -2.5% adjusted for alveolar volume; moderate evidence), 12 months (MD, -5.90%; 95% CI, -8.4% to -3.4% adjusted for alveolar volume; moderate evidence), and 18 months (MD, -3.26%; 95% CI, -6.1% to -0.4%; moderate evidence), but not at 24 months. There were no differences in FVC % predicted, mortality, or quality-of-life outcomes, but participants were more likely to prematurely discontinue cyclophosphamide compared with mycophenolate (relative risk, 1.70; 95% CI, 1.10-2.63; high-certainty evidence). Conclusions: A review of the published evidence shows that cyclophosphamide is effective in SSc-ILD compared with placebo, with an increased risk of side effects. However, mycophenolate may be equivocal or better than cyclophosphamide. Clinicians and patients should weigh the potential benefits and risks with respect to individual patient circumstances and preferences.

The side-effects of cyclop hosphamide in the treatment of systemic autoimmune diseases

General Adverse Response to Cyclophosphamide in Chinese Patients with Systemic Autoimmune Diseases in Recent Decade — a Single-Center Retrospective Study

The Effect of Cyclophosphamide Treatment on the Prognosis of Patients with Systemic Lupus Erythematosus

Low Dosage Use of Cyclophosphamide Improves the Survival of Patients with Systemic Lupus Erythematosus.

Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide

[A Multicenter Study on the Tolerance of Intravenous Low-Dose Cyclophosphamide in Systemic Lupus Erythematosus].

Analysis on adverse drug reactions caused by cyclosporine in patients with rheumatic diseases

Efficacy of low-dose intravenous cyclophosphamide in combination with immunoclearance in treatment of systemic lupus erythematosus

Premature ovarian failure in systemic lupus erythematosus patients: is it related to cyclophosphamide treatment?

Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment

Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report

The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease

Metabolic profiling study on potential toxicity and immunotoxicity-biomarker discovery in rats treated with cyclophosphamide using HPLC-ESI-IT-TOF-MS.

Efficacy and safety of oral versus intravenous cyclophosphamide in treatment of connective tissue disease‐related interstitial lung disease

The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials

Impact of Systemic Lupus Erythematosus on Ovarian Reserve in Premenopausal Women Before Receiving Cyclophosphamide Therapy: Evaluation Using Anti-Müllerian Hormone

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis

Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.

Genetic Polymorphisms of Cyclophophamide-Metabolizing Enzymes and Their Association with Chemotherapy Responses in Breast Cancer